Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to airway colonization by Aspergillus fumigatus in patients with asthma and cystic fibrosis. The pathophysiology of ABPA involves a complex interplay between the fungus and the host immune response, which causes persistent inflammation and tissue damage. Patients present with chronic cough, wheezing, and dyspnea due to uncontrolled asthma. Characteristic symptoms include the expectoration of brownish mucus plugs. Radiographic findings often reveal fleeting pulmonary infiltrates, bronchiectasis, and mucus impaction. However, the definitive diagnosis of ABPA requires a combination of clinical, radiological, and immunological findings. The management of ABPA aims to reduce symptoms, prevent disease progression, and minimize the future risk of exacerbations. The treatment approach involves systemic glucocorticoids or antifungal agents to suppress the inflammatory response or fungal growth and prevent exacerbations. Biological agents may be used in patients with severe disease or glucocorticoid dependence. This review provides an overview of the clinical manifestations and current treatment options for ABPA.

过敏性支气管肺曲霉病（ABPA）是哮喘和囊性纤维化患者对烟曲霉定植气道的复杂过敏反应。ABPA 的病理生理学涉及真菌和宿主免疫反应之间复杂的相互作用，从而导致持续的炎症和组织损伤。患者因哮喘不受控制而出现慢性咳嗽、喘息和呼吸困难。特征性症状包括咳出褐色粘液塞。放射线检查结果常常显示短暂的肺部浸润、支气管扩张和粘液嵌塞。然而，ABPA 的明确诊断需要结合临床、放射学和免疫学结果。ABPA 的管理旨在减轻症状、预防疾病进展并尽量减少未来病情恶化的风险。治疗方法涉及全身性糖皮质激素或抗真菌药物，以抑制炎症反应或真菌生长并防止病情恶化。生物制剂可用于患有严重疾病或糖皮质激素依赖的患者。本综述概述了 ABPA 的临床表现和当前的治疗方案。